查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1964167

孤兒藥市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類型、疾病類型、分銷管道、地區和競爭格局分類，2021-2031年

Orphan Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Drug Type, By Disease Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球孤兒藥市場預計將從 2025 年的 2,125.9 億美元成長到 2031 年的 4,430.7 億美元，複合年成長率為 13.02%。

該市場主要由針對罕見疾病（通常病情嚴重）的特效藥物組成，這些疾病影響的患者群體有限。該領域的成長主要得益於監管激勵措施，例如市場獨佔權和稅額扣抵，以及基因組學的進步，這些進步使得標靶治療成為可能。這些進步旨在彌合患者照護的巨大差距。根據美國製藥商協會 (PhRMA) 預測，到 2024 年，在已知的約 7000 種罕見疾病中，只有 5% 的疾病能夠獲得治療方法，這表明存在巨大的未滿足需求。這種情況正在推動持續的投資和創新。

市場概覽
預測期 2027-2031
市場規模：2025年 2125.9億美元
市場規模：2031年 4430.7億美元
複合年成長率：2026-2031年 13.02%
成長最快的細分市場 生物
最大的市場 北美洲

儘管取得了這些進展，但高昂的治療費用仍然是市場成長的主要障礙，也使全球報銷流程變得複雜。支付者越來越關注這些小眾治療方法的溢價，導致談判缺日持久，病人就醫延遲。鑑於大量昂貴的先進治療方法湧入市場，如何在維持創新獎勵和控制醫療預算之間取得平衡，使得這場衝突尤為突出。因此，如何成功克服這些財務障礙，仍然是業內相關人員面臨的重大挑戰。

市場促進因素

政府獎勵措施和孤兒藥法規的實施是全球孤兒藥市場的主要驅動力。監管機構透過提供實質激勵措施，例如臨床試驗稅額扣抵、處方藥用戶費用豁免以及延長商業性獨佔期，來降低開發罕見疾病治療方法相關的商業風險。這些誘因從根本上改變了藥物研發的經濟模式，鼓勵藥廠開發那些原本在經濟上不可行治療方法。這些政策的成功體現在監管核准記錄中。根據美國食品藥物管理局（FDA）於2024年1月發布的《2023年新療法核准報告》，2023年核准的55種新藥中有28種被認定為孤兒藥，這表明優先考慮罕見疾病治療創新的這一框架卓有成效。

同時，基因組學和精準醫療技術的進步正在重塑市場格局，加速開發罕見疾病潛在遺傳因子的高標靶化治療方法。識別特定生物標記和基因突變的能力使製造商能夠開發根治性治療方法，例如基因療法，而不僅僅是控制症狀。這項技術進步吸引了大量投資，並催生了突破性產品。根據再生醫學聯盟於2024年1月發布的《產業趨勢簡報》，2023年有五種用於治療罕見疾病的新型基因療法獲得監管機構核准，創下該領域的新紀錄。這些特藥的商業性成功也得到了Astra Zeneca在2024年報告稱，其罕見疾病業務在2023年創造了77.6億美元的收入，年增12%，這主要得益於市場對這些先進療法的需求。

市場挑戰

高昂的治療費用以及由此導致的複雜報銷流程是全球孤兒藥市場成長的主要障礙。儘管研發公司為了收回巨額研發投入而設定高價，但全球醫療保險公司日益關注藥物的成本效益和臨床價值。這種財務摩擦迫使企業採取嚴格的成本控制策略和漫長的價格談判，實際上導致監管核准與實際市場准入脫鉤。如果保險覆蓋被延遲或拒絕，企業將面臨“上市空檔期”，即已通過核准產品無法產生收入，導致即使存在臨床解決方案，市場規模也會萎縮。

這種充滿挑戰的環境迫使製造商應對難以預測的時間表，從而削弱了小眾治療方法的商業性可行性。據歐洲製藥工業協會聯合會（EFPIA）稱，這些行政和財務障礙導致到2024年，歐洲患者獲得創新藥物的平均等待時間為578天。如此漫長的等待直接縮短了可用於投資回收的市場獨佔期。因此，難以確保及時獲得報銷，使得相關人員不願優先考慮在價格敏感地區推出產品，最終限制了該行業的全球擴張和財務表現。

市場趨勢

將人工智慧 (AI) 應用於孤兒藥研發，從根本上加速了針對醫療數據有限的疾病的治療標靶的發現。透過使用機器學習演算法分析複雜的生物資料集，研發人員可以比傳統方法更快預測藥物的療效和安全性，從而顯著降低孤兒藥研發中通用的高失敗率。這種技術有效性的展現，正推動大規模資本投資湧入專注於特定適應症的AI原生生物技術公司。例如，2024年8月，Healx在一份題為「Healx宣布完成4700萬美元C輪資金籌措」的新聞稿中宣布，該公司已獲得4700萬美元資金，用於推進其針對罕見癌症、腎臟疾病和神經發育障礙的旗艦AI驅動藥物研發管線，特別是將其針對1型神經纖維瘤的旗艦項目推進至IIAI驅動藥物。

同時，策略性併購和授權協議的激增正在重塑競爭格局，大型製藥企業正尋求透過風險較低的後期罕見疾病資產快速強化其產品組合。產業領導者不再僅僅依賴內部藥物研發週期，而是透過收購專業生技公司，即時獲得有前景的治療方法，以滿足尚未滿足的醫療需求。這種整合策略的典型例子是針對嚴重創新療法的高價值交易。在2024年2月發布的公告「諾華透過收購MorphoSys AG加強腫瘤產品線」中，諾華宣布以27億歐元收購MorphoSys，從而獲得perabrecib（一種治療骨髓纖維化——一種罕見骨髓癌的創新療法）的全球獨家權益。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球孤兒藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（生物製藥、非生物製藥）
    • 疾病類型（腫瘤科、血液科、神經科、循環系統、其他）
    • 分銷管道（醫院、藥局、線上銷售、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美孤兒藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲孤兒藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區孤兒藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲孤兒藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲孤兒藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球孤兒藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • GSK plc
  • Alexion Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Merck KgaA
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23861

The Global Orphan Drugs Market is projected to expand from USD 212.59 Billion in 2025 to USD 443.07 Billion by 2031, exhibiting a CAGR of 13.02%. This market consists of specialized medications designed for rare and typically severe disorders that affect limited patient populations. The sector's growth is largely fueled by regulatory incentives, such as market exclusivity and tax credits, alongside advancements in genomics that facilitate targeted therapies. These developments aim to fill critical gaps in patient care; according to the Pharmaceutical Research and Manufacturers of America, in 2024, treatments were available for only 5% of the approximately 7,000 known rare diseases, creating a widespread unmet need that drives sustained investment and innovation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 212.59 Billion
Market Size 2031USD 443.07 Billion
CAGR 2026-203113.02%
Fastest Growing SegmentBiological
Largest MarketNorth America

Despite these advancements, the high cost of treatment presents a major hurdle to market growth by complicating global reimbursement processes. Payers are increasingly examining the premium pricing of these niche therapies, resulting in extended negotiations that delay patient access. This conflict between maintaining incentives for innovation and managing healthcare budgets is particularly intense given the influx of expensive advanced therapies. Consequently, successfully navigating these financial barriers remains a significant challenge for stakeholders within the industry.

Market Driver

The implementation of favorable government incentives and Orphan Drug Acts serves as the primary catalyst for the Global Orphan Drugs Market. Regulatory bodies mitigate the commercial risks involved in developing treatments for small patient populations by providing substantial benefits, including tax credits for clinical trials, prescription drug user fee waivers, and extended periods of market exclusivity. These incentives fundamentally transform the economic model of drug development, encouraging pharmaceutical companies to pursue therapies that might otherwise be financially impractical. The success of these policies is highlighted by regulatory outcomes; according to the FDA's "New Drug Therapy Approvals 2023" report from January 2024, 28 of the 55 novel drugs approved in 2023 were designated as orphan drugs, emphasizing the effectiveness of these frameworks in prioritizing rare disease innovation.

Concurrently, advancements in genomics and precision medicine technologies are reshaping the market by facilitating the development of highly targeted therapies that address the underlying genetic causes of rare conditions. The capacity to identify specific biomarkers and genetic mutations allows manufacturers to create curative treatments, such as gene therapies, rather than simply managing symptoms. This technological evolution has drawn significant investment and produced breakthrough products; the Alliance for Regenerative Medicine reported in their January 2024 "State of the Industry Briefing" that regulators approved five new gene therapies for rare disorders in 2023, setting a record for the sector. The commercial success of these specialized medicines is further evidenced by major industry players, such as AstraZeneca, which reported in 2024 that its rare disease business generated $7.76 billion in revenue during 2023, a 12% increase driven by demand for these advanced therapeutics.

Market Challenge

The high cost of treatment and subsequent complications in reimbursement processes create a significant barrier to the Global Orphan Drugs Market's growth. As developers establish premium prices to recoup substantial research investments, healthcare payers worldwide are increasingly scrutinizing the clinical value relative to the expense. This financial friction demands rigorous cost containment strategies and prolonged price negotiations, effectively disconnecting regulatory approval from actual market entry. When coverage is delayed or denied, companies encounter a substantial launch gap where approved products fail to generate revenue, thereby reducing the addressable market size despite the availability of a clinical solution.

This difficult environment compels manufacturers to deal with unpredictable timelines that compromise the commercial viability of niche therapies. According to the European Federation of Pharmaceutical Industries and Associations, the average waiting time for patients to access innovative new medicines across Europe reached 578 days in 2024 due to these administrative and financial obstacles. Such lengthy delays directly shorten the market exclusivity period available for recovering investments. Consequently, the challenge of securing timely reimbursement deters industry stakeholders from prioritizing launches in price-sensitive regions, which ultimately restricts the sector's global expansion and financial performance.

Market Trends

The integration of artificial intelligence into rare disease drug discovery is fundamentally accelerating the identification of therapeutic targets for conditions with limited medical data. By utilizing machine learning algorithms to analyze complex biological datasets, developers can predict drug efficacy and safety profiles more quickly than traditional methods permit, significantly lowering the high attrition rates common in orphan drug research. This technological validation is stimulating substantial capital investment in AI-native biotech firms focused on niche indications. For instance, according to a press release from Healx in August 2024 regarding its "Healx Announces $47 million Series C Financing," the company secured $47 million to advance its AI-enabled pipeline of medicines for rare oncology, renal, and neurodevelopmental disorders, specifically moving its lead program for neurofibromatosis Type 1 into Phase 2 clinical trials.

Simultaneously, a surge in strategic mergers, acquisitions, and licensing agreements is reshaping the competitive landscape as major pharmaceutical companies aim to rapidly strengthen their portfolios with de-risked, late-stage rare disease assets. Instead of relying solely on internal discovery timelines, industry leaders are acquiring specialized biotechs to gain immediate access to promising therapies that address significant unmet needs. This consolidation strategy is illustrated by high-value transactions targeting novel treatments for severe conditions; according to a February 2024 announcement titled "Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG," Novartis entered an agreement to acquire MorphoSys for €2.7 billion to obtain exclusive worldwide rights to pelabresib, a novel treatment for the rare bone marrow cancer myelofibrosis.

Key Market Players

  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • GSK plc
  • Alexion Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Merck KgaA
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.

Report Scope

In this report, the Global Orphan Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orphan Drugs Market, By Drug Type

  • Biological
  • Non-biological

Orphan Drugs Market, By Disease Type

  • Oncology
  • Haematology
  • Neurology
  • Cardiovascular
  • Others

Orphan Drugs Market, By Distribution Channel

  • Hospital
  • Pharmacy
  • Online Sales
  • Others

Orphan Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orphan Drugs Market.

Available Customizations:

Global Orphan Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orphan Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Biological, Non-biological)
    • 5.2.2. By Disease Type (Oncology, Haematology, Neurology, Cardiovascular, Others)
    • 5.2.3. By Distribution Channel (Hospital, Pharmacy, Online Sales, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Orphan Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Disease Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Orphan Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Orphan Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Disease Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Orphan Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Disease Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Orphan Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Orphan Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Orphan Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Orphan Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Orphan Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Disease Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Orphan Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Disease Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Orphan Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Orphan Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Orphan Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Orphan Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Orphan Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Orphan Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Orphan Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Orphan Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Disease Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Orphan Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Disease Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Orphan Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Disease Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Orphan Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Orphan Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Orphan Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Orphan Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Orphan Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Sanofi SA
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. GSK plc
  • 15.6. Alexion Pharmaceuticals, Inc.
  • 15.7. AbbVie Inc.
  • 15.8. Merck KgaA
  • 15.9. Johnson & Johnson
  • 15.10. F. Hoffmann-La Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer